A new preclinical study from Weill Cornell Medicine and Cornell University shows that ultrasmall silica nanoparticles (C' dots) kill prostate tumor cells through ferroptosis and convert the immune microenvironment from cold to hot, enhancing immunotherapy efficacy. C' dots trigger ferroptosis by delivering iron ions into tumor cells, causing membrane degradation.
The particles convert immune cells from inert to active antitumor states, sensitizing tumors to checkpoint blockade. In mouse models, combination therapy led to complete remissions in up to 50% of treated animals.
No toxicity was observed in healthy tissues, including the spleen. The findings suggest a new paradigm for treating aggressive prostate cancer by combining direct tumor killing with immune remodeling.